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ABSTRACT
Background. The inflammatory process in patients with chronic obstructive pulmonary disease (COPD) 
interferes with the normal function of respiratory lung. There is strong evidence indicating that inflammatory 
process in patients with COPD may activate  blood coagulation. However, little is known about the role of 
tissue factor (TF) pathway in the coagulation system activation in COPD.
Objectives. The aim of the study has been to evaluate the concentration of selected parameters of coagu-
lation process, including TF and tissue factor pathway inhibitor (TFPI), in plasma of patients with COPD.
Patients and methods. The study included 66 patients with COPD at different stages of disease according 
to GOLD 2006, mean  age of 60.4 years. The control group consisted of 25 healthy volunteers (non-smok-
ers). Total TF and TFPI concentrations and other haemostatic parameters were measured using Enzyme 
Linked Immunosorbent Assay (ELISA).
Results.  Significantly higher concentrations of TF and TFPI (p = 0.03; p = 0.004, respectively) were ob-
served in patients with COPD. The level of fibrinogen was also higher in the study group than in controls 
(p = 0.002). However, the activated partial thromboplastin time (aPTT) was shortened in COPD patients 
as compared with the control group (p = 0.0001).
Conclusion. The study showed that in patients suffering from COPD, the stimulation of the tissue factor- 
-dependent activation of coagulation is observed.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
one of the most common diseases in developed coun-
tries. Epidemiology data shows a clear global increase 
in the death rate as a result of COPD. It is estimated that 
COPD will be the third leading cause of death worldwide 
by 2020 and the fifth most common disease causing 
the incapacity for work [1, 2].
Chronic obstructive pulmonary disease is a new 
designation connecting diseases so far referred to as 
chronic bronchial inflammation and pulmonary em-
physema. These two diseases (with a few exceptions) 
are the result of smoking, and both occur most often 
simultaneously with a different intensity. In 1964, the 
Americans suggested the new name to combine both 
diseases [3, 4].
Chronic obstructive pulmonary disease, according 
to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), is a disease which can be prevent-
ed and treated effectively. Pulmonary changes are 
characterized by partially reversible limiting of the air 
flow through the respiratory tract. This is a progressive 
process, developed as the effect of impaired inflamma-
tory response of lungs to the action of harmful dusts 
or gasses [4–6].
Almost 80–90% of patients with COPD are active 
or former smokers which makes smoking the main 
etiopathogenetic factor [7, 8]. Besides nicotinism, the 
following risk factors are present among the environ-
mental factors,: intense occupational exposure to dusts 
and chemical substances, atmospheric air pollution, 
infections of the respiratory system in the childhood, 
reoccurring bronchial-pulmonary infection as well as low 
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socioeconomic status [9]. The best documented individ-
ual factor is rare inborn a1-antitrypsin deficiency of the 
main circulating inhibitor of serine proteinases [10, 11].
In patients with COPD, the inflammatory process 
disturbs the correct respiratory lung activity which leads 
to accumulation of the following inflammatory cells in 
the lungs: neutrophils, macrophages, lymphocytes (es-
pecially CD 8+, Th1 and Th2) and B lymphocytes. The 
activated inflammatory cells release various mediators 
which damage the structure of lungs and (or) sustain 
neutrophil inflammation. The inflammatory process 
disturbs the balance between proteases (enzymes 
breaking down lung proteins) and antiproteases (en-
zymes protecting lung proteins from degradation) [12]. 
The pathomechanism of bronchi-pulmonary changes 
involves also the participation of oxidants found in the 
tobacco smoke and released from flowing neutrophils 
and macrophages [13].
The coagulation process activation is an element 
of inflammatory reaction in COPD. The crucial role in 
coagulation cascade is played by platelets, endothe-
lium cells, adhesion molecule and plasma coagulation 
proteins. The inflammation results in an increased ex-
pression of the cytokines leading to blood coagulation 
activation [14], which, in turn, can cause thromboem-
bolic complications. The research of the last few years 
demonstrates the primary role of the tissue factor (TF) 
in the blood coagulation activation. The analysis of 
available literature shows that only few papers deal 
with the TF role in the pathogenesis of haemostasis 
disorders in COPD patients. The aim of the study has 
been to assess the concentration of tissue factor path-
way inhibitor (TFPI), tissue factor (TF), soluble form of 
thrombomodulin (sTM), thrombin-antithrombin complex 
(TAT), fibrinogen, and the activity of protein C in patients 
with COPD.
Patients and methods
Sixty-six patients with chronic obstructive pulmo-
nary disease were recruited at various disease severity 
stages (GOLD 2006): stage (FEV1 > 80%) — 8 pa-
tients, II stage (FEV1 > 80 to < 50) — 20 patients, 
III stage (FEV1 > 30 to < 50) — 22 patients and 
IV stage (FEV1 < 30) — 16 patients, treated in Depart-
ment of Pulmonary Diseases and Respiratory Failure, 
Kuyavian-Pomeranian Regional Pulmonology Centre, 
Bydgoszcz, Poland.
The study group consisted of 18 females and 
48 males aged from 40 to 82 (the average age was 
60.4 years). disease advancement level was identified 
on the basis of interviews, the examination of symptoms 
and spirometry. The disease symptoms lasted 3 to 
32 years. The exclusion criteria included the presence 
of coexisting diseases such as hypertension, diabe-
tes, glomerulonephritis, surgery < 3 months, COPD 
exacerbation < 3 months, receiving anticoagulants, 
thrombolytics, and antiplatelet drugs, thromboembolic 
disease and pulmonary embolism < 6 months. The in-
clusion criteria were: age > 40 years, current or former 
smoker (> 10 pack-years), and a stable disease period. 
The patients were treated according to the GOLD 2006.
The control group consisted of 25 healthy volun-
teers, non-smokers with normal spirometry, matched 
for age and sex. 
Written informed consent was obtained from each 
participant before entering the study. The study was 
approved by the Bioethics Committee of the Nicolaus 
Copernicus University in Toruń, Collegium Medicum in 
Bydgoszcz, Poland.
Venous blood (4.5 mL) for tests of TF, TFPI, fibrin-
ogen, sTM, activity of protein C, PT, INR, aPTT was 
collected in a fasting state into cooled tubes (Becton 
Dickinson Vacutainer® System, Plymouth, UK) contain-
ing 0.13 mol/L trisodium citrate (the final blood — an-
ticoagulant ratio was 9:1) after 30 min of rest between 
7.30 and 9.30 a.m. and after a 12 h overnight fast. The 
blood samples were immediately mixed and centrifuged 
at 3000 × g at + 4°C for 20 min. The platelet-poor plas-
ma was divided into 200 µL Eppendorf-type tubes and 
then the samples were frozen at –80°C (according to 
the manufacturer’s procedures) until assayed, however, 
no longer than six months. 
Hemostatic assays
The concentrations of TF, TFPI sTM were determined 
by the Enzyme Linked Immunosorbent Assay (ELISA) 
(IMUBIND® total TF, IMUBIND® total TFPI, IMUBIND® 
Thrombomodulin, respectively; American Diagnostica 
Inc., Greenwich, USA). The TAT concentration was 
determined by ENZYGNOST® TAT micro, Behring, Mar-
burg, France. However, the concentration of fibrinogen, 
activity of protein C, PT, INR, aPTT were measured in 
an automated coagulometer CC-3003 apparatus and 
reagents produced by Bio-Ksel Co, Grudziądz, Poland.
Statistical analysis
The statistical analysis was performed using the 
statistics program Statistica v. 9 StatSoft® software 
(StatStoft®, Cracow, Poland). The Shapiro–Wilk test was 
used to assess the distribution normality. ,The arithmetic 
mean (X) and standard deviations (SD) were determined 
for the variables with normal distribution. The median 
(Me), lower quartile (Q1), and upper quartile (Q3) were 
applied for the values with non-normal distribution. 
The significance of differences between the groups 
for the variables analysed with normal distribution was 
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Figure 2. aPTT in the study group and in the control groupFigure 1. The concentration of fibrinogen in the study group 
and in the control group
examined using the classical t-Student test and for 
other variables Mann-Whitney U test rank-sum test was 
used. The p-values < 0.05 were considered statistically 
significant. 
Results
Table 1 shows the selected parameters of haemo-
stasis in patients with COPD and the control group. No 
significant differences were observed in the concentra-
tion of TAT complexes and sTM, also in prothrombin 
time, INR, and activity of protein C in the study and in 
the control groups.
Figures 1 and 2 present significantly higher concen-
tration of fibrinogen in the study group as compared 
with the control group (p = 0.002) and shorter aPTT 
in the study group (p < 0.0001). Significantly higher 
levels of TF and TFPI were noted in the study group as 
compared with the control group (p = 0.03; p = 0.004, 
respectively) (Figs. 3 and 4).
Discussion
The results of the study have shown that the in-
creased concentration of TF, TFPI, fibrinogen and 
shortened activated partial thromboplastin time were 
observed in patients with COPD.
 Activation of the extrinsic blood coagulation 
pathway plays a crucial role in the complications of 
thromboembolism occurring in cancer, atherosclerosis 
and sepsis [15]. The tissue factor is a fixed component 
of cell membranes, it also appears in cytosol and the 
intercellular matrix as well as in plasma and fluids of 
body cavities. High concentrations of tissue factor are 
observed in tunica adventitia of blood vessels Moreover, 
the brain, lungs and placenta are also rich in TF [16]. 
TF is a glycoprotein; its chain is composed of three 
domains: submembrane, intramembrane and over-
membrane (transmembrane protein) and it is mainly 
exposed by cells with locations physically separate 
from the circulating blood. In normal conditions, tissue 
cells and endothelial cells do not release the tissue 
factor and, therefore, its concentration in plasma in 
healthy people is low. However, it plays a key role in 
the protection against bleeding as a result of tissue 
damage. Blood vessels injury leads to the initiation of 
blood coagulation activation via the TF [17].
Present studies have demonstrated that the average 
value of TF in plasma of healthy people is 83.08 pg/mL. 
The available literature analysis shows a large dis-
crepancy between test results for TF levels in healthy 
individuals. Radziwon et al. noted that the average 
Table 1. Chosen parameters of haemostasis in the study group with COPD and in the control group
Study group (N = 66) Control group (N = 25) 
p value
M/Me SD/Q1,Q3 M/Me SD/Q1,Q3
PT [s] 14.46 1.64 15.00 0.98 0.1289
INR 1.03 0.12 1.07 0.07 0.1193
Protein C (%) 96.89 17.65 103.64 11.69 0.0807
TAT [μg/L] 1.79 1.38, 2.62 2.49 1.42, 5.11 0.0732
sTM [ng/mL] 2.00 1.59, 2.30 1.90 1.52, 2.42 0.9394
M/Me — mean or median; SD/Q1, Q3 — standard deviation or upper and lower quartile
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concentration of TF  amounted to  226 ± 86.19 pg/mL 
in the group of 100 healthy people. Pawlak et al. 
observed that the TF concentration was 112 pg/mL 
among 20 healthy people. However, Bronowicz et al., 
in the group of 35 healthy blood donors, found that the 
average concentration of TF was equal to 87.58 pg/mL, 
most similar to the TF concentration recorded in the 
present research [18–20].
Blood coagulation disorders, particularly TF-de-
pendent hypercoagulability, are  the cause of many 
serious diseases such as: atherosclerosis, sepsis, ma-
lignancies, acute respiratory distress syndrome (ARDS) 
and glomerulonephritis. The TF source starting blood 
coagulation can cover: cancer cells, tissues damaged 
by injury or surgery, tissues of dead foetus, procoagu-
lating material from placenta. Bacterial endotoxins and 
cytokines, such as TNF-a, IL-1 cause endothelial cell 
damage and the TF exposure located in the suben-
dothelial layer. Mucopolysaccharides of bacterial cell 
membranes are capable of activating blood coagulation 
in a similar way as endotoxin. In addition, tissue factor 
may be present on tumour cells or macrophages, which 
are activated by endotoxin or cytokines [17, 21].
Papers on the activation of the coagulation process 
occurring in lung diseases have been found in the 
available literature. An increased fibrin accumulation 
in the pulmonary interstitial space was observed in 
patients with idiopathic pulmonary fibrosis, in sclero-
derma, acute lung injury and ARDS. In most of these 
syndromes increased local production of thrombin was 
also observed. An elevated TF level, observed in bron-
choalveolar lavage fluid (BALF), recorded in this group 
of diseases, indicates at least a partial participation of 
the extrinsic coagulation pathway in the activation of 
prothrombin to thrombin [22, 23].
In the available literature there seem to be few stud-
ies about TF in patients with COPD. 
Vaidyula and colleagues found elevated activity of tis-
sue factor (TF — PCA, TF — procoagulant activity) among 
11 patients with COPD as compared with the control group 
(52.3 U/mL vs. 20.7 U/mL) [24]. In our study, elevated 
levels of the total pool of TF in patients prove an increased 
blood coagulation activation by extrinsic pathway.
The key role played by the TF in initiating the 
blood coagulation cascade with subsequent thrombin 
generation, platelet activation and fibrin deposition is 
controlled by the tissue factor pathway inhibitor. Endo-
thelium produces TFPI, which is a Kunitz-type protein 
with molecular weight of 42 kD with three inhibitor 
domains. The first of them is bonded with a complex 
of TF and factor VII, the second one involves an active 
factor X, while the third one is responsible for binding 
of TFPI to heparin and lipoproteins. TFPI associated 
with endothelium accounts for 50–90% of the total pool 
and it is released into plasma after heparin injection. 
The plasma concentration of inhibitor increases 2 to 
10 times after intravenous and subcutaneous injections 
of heparin and other glycosaminoglycans [20].
According to Radziwon, the concentration and 
activity of TFPI in plasma of healthy people varies in 
a fairly wide range: 50–170 ng/mL [21]. In Kłoczko’s 
opinion, the average concentration of TFPI in the 
plasma of healthy people is approximately 100 ng/mL, 
which corresponds to the level of about 2.5 nmol/L [25]. 
Similarly, according to Naumnik et al., the physiological 
concentration of TFPI in plasma is low and amounts 
to approximately 2.5 nmol/L [17]. The concentration 
of TFPI found in the present study in healthy people 
amounts to 96.12 ng/mL and is similar to the results of 
most studies available in the literature.  
Figure 4. TFPI in the study group and in the control group Figure 3. TF in the study and in the control group
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Literature reports on TFPI concentration being 
elevated in many clinical states: it increases during 
pregnancy by 29%, in bacteremia by 70%, in metastatic 
cancer by 83%, in ARDS by 47%, in hypercholesterol-
emia from 30 to 53%, after t-PA injection by 60%, after 
exercise from 20 to 40% [17].
An increased TFPI content was observed in patients 
with advanced malignancy of colorectal, pancreatic, gas-
tric, breast and prostate. Increasing concentrations of 
TFPI occur with disease progression, however, so far TFPI 
production by tumor cells has not been found [20, 26]. 
The largest TFPI concentration has been noted by the 
authors in acute and chronic myeloid leukaemia. Sig-
nificantly increased TFPI levels were also observed in 
patients with urinary tract cancer (kidney and bladder 
cancer) as compared with healthy subjects [21]. 
Many researches indicate the importance of the TFPI 
as a risk marker for cardiovascular disease. Ott et al. 
noticed increased TFPI concentrations in patients with 
acute myocardial infarction undergoing angioplasty 
with stent placement as compared with the patients 
with stable angina following the same procedure [27]. 
He et al. noted an elevated TFPI level correlating with 
an increasing TF level in patients with acute myocardial 
infarction,  and lower TFPI concentration, despite an in-
creasing TF, in patients with acute ischemic stroke [28].
The authors of the majority of papers about TFPI in 
various thrombotic states are of the opinion that high 
TFPI concentration is a symptom of strong inhibition 
of TF activating blood coagulation, while reduced TFPI 
concentration is an expression of inhibitor consumption 
in this mechanism and the evidence of prothrombotic 
risk. Different attempts have been made to use of TFPI 
recombinant as an antithrombotic drug [28].
Our study demonstrates significantly higher con-
centrations of this inhibitor in patients with COPD. The 
research on TFPI in patients with COPD from only one 
centre has been found in the literature. Cella et al. report-
ed elevated TFPI concentration in patients with COPD 
suggesting that endothelial cells are potentially able to 
produce natural inhibitors of blood coagulation [5, 29].
As far as endothelial TFPI origin is concerned, its 
high concentration in patients’ blood indicates endo-
thelial vascular damage. On the other hand, it is also 
a defence mechanism against the development of 
blood clots. In patients with COPD, hypoxemia, which 
can cause endothelial damage, is a factor increasing 
prothrombotic processes. Lewczuk et al. suggest that 
the coexistence of COPD and chronic thromboembolic 
pulmonary hypertension increased their 18-month risk 
of death twice [30].
The literature analysis of the TFPI role in blood 
coagulation process disorders shows that increased 
TFPI level plays an important part in inhibiting blood 
coagulation process initiated by the tissue factor.
Our research demonstrated higher concentration 
of fibrinogen in general group of patients with COPD. 
High concentration of fibrinogen in COPD patients 
undoubtedly increases the blood viscosity, platelets 
activation, and it is an important factor increasing 
blood coagulability.
The aPTT value was significantly shortened as 
compared with healthy people, indicating a coagulation 
activation in the patients with COPD and the intrinsic 
pathway, which, in the light of current trends, is less 
effective in creating thrombin.
In conclusion, it should be noted that among pa-
tients with COPD, regardless of a greater intensity of 
the disease, the risk of thrombotic complication occurs, 
expressed by increased concentration of TF and fibrin-
ogen. This process is limited by effective action of the 
natural coagulation inhibitors (TFPI). However, as it 
comes from the analysed literature, the acute inflamma-
tion can activate the coagulation process, which creates 
a significant risk of thromboembolic complications in 
patients with COPD during the disease exacerbation.
Conclusions
The study demonstrates the coagulation activation 
(higher TF and fibrinogen, shortened aPTT) in patients 
with COPD in a stable disease phase. However, inhibit-
ing the extrinsic coagulation pathway is expressed by 
elevated levels of TFPI in patients with COPD.
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